All In Biotech

Drug Trial Radar · NCT04609904

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter Variable Length Study to Assess the Efficacy and Safety of PT010 Relative to PT009 and Symbicort® in Adult and Adolescent Participants With Inadequately Controlled Asthma

Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,187 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,187

Actual

Start

Mar 1, 2021

Primary completion

Mar 20, 2025

Study completion Mar 20, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care.

Conditions

  • Asthma

Interventions

  • BGF MDI 320/28.8/9.6 μgDrug

    Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler

  • BGF MDI 320/14.4/9.6 μgDrug

    Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler

  • BFF MDI 320/9.6 μgDrug

    Budesonide and formoterol fumarate metered dose inhaler

  • BFF pMDI 320/9 μgDrug

    Budesonide/formoterol fumarate pressurized metered dose inhaler

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in FEV1 AUC0-3 (L) at Week 24Time frame: Week 24
  2. Pooled (LOGOS/KALOS): Rate of Severe Asthma ExacerbationsTime frame: Up to 52 Weeks

Locations

317 sites in 16 countries. Site status is shown where the registry gives one.

  • Research Site

    Chandler, Arizona

  • Research Site

    Tempe, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Hot Springs, Arkansas

  • Research Site

    Bakersfield, California

  • Research Site

    Carlsbad, California

  • Research Site

    Huntington Beach, California

  • Research Site

    Lancaster, California

  • Research Site

    Long Beach, California

  • Research Site

    Mission Viejo, California

  • Research Site

    North Hollywood, California

  • Research Site

    Northridge, California

  • Research Site

    Rancho Cucamonga, California

  • Research Site

    Sacramento, California

  • Research Site

    San Diego, California

  • Research Site

    San Jose, California

  • Research Site

    Ventura, California

  • Research Site

    Walnut Creek, California

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Wheat Ridge, Colorado

  • Research Site

    Newark, Delaware

  • Research Site

    Boca Raton, Florida

  • Research Site

    Clearwater, Florida

  • Research Site

    Clearwater, Florida

  • Research Site

    Cutler Bay, Florida

  • Research Site

    DeBary, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Lakeland, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Acworth, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Snellville, Georgia

  • Research Site

    Boise, Idaho

  • Research Site

    Chicago, Illinois

  • Research Site

    Normal, Illinois

  • Research Site

    Peoria, Illinois

  • Research Site

    Evansville, Indiana

Showing 40 of 317 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.